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Abstract
Despite the important diagnostic value of evaluating antibody responses to individual human pathogens, antibody
profiles against multiple infectious agents have not been used to explore health and disease mainly for technical
reasons.  We hypothesized that the interplay between infection and chronic disease might be revealed by profiling
antibodies against multiple agents. Here, the levels of antibodies against a panel of 13 common infectious agents
were evaluated with the quantitative Luciferase Immunoprecipitation Systems (LIPS) in patients from three disease
cohorts including those with pathogenic anti-interferon-γ autoantibodies (IFN-γ AAB), HIV and Sjögren’s syndrome
(SjS) to determine if their antibody profiles differed from control subjects.  The IFN-γ AAB patients compared to
controls demonstrated statistically higher levels of antibodies against VZV (p=0.0003), EBV (p=0.002), CMV
(p=0.003), and C. albicans (p=0.03), but lower antibody levels against poliovirus (p=0.04). Comparison of HIV
patients with blood donor controls revealed that the patients had higher levels of antibodies against CMV (p=0.0008),
HSV-2 (p=0.0008), EBV (p=0.001), and C. albicans (p=0.01), but showed decreased levels of antibodies against
coxsackievirus B4 (p=0.0008), poliovirus (p=0.0005),   and HHV-6B (p=0.002). Lastly, SjS patients had higher levels
of anti-EBV antibodies (p=0.03), but lower antibody levels against several enteroviruses including a newly identified
picornavirus, HCoSV-A (p=0.004), coxsackievirus B4 (p=0.04), and poliovirus (p=0.02). For the IFN-γ AAB and HIV
cohorts, principal component analysis revealed unique antibody clusters that showed the potential to discriminate
patients from controls.  The results suggest that antibody profiles against these and likely other common infectious
agents may yield insight into the interplay between exposure to infectious agents, dysbiosis, adaptive immunity and
disease activity.
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Introduction
Although there are many known pathogenic viruses and
microbes (e.g. HIV, HBV and Mycobacterium tuberculosis) that
cause human disease [1], a comprehensive catalogue of
human infectious agents and their impact on health remains
largely incomplete. A previous estimate placed the number of
human pathogens at approximately 1400 distinct agents [2],
but in the last decade many new infectious viruses and bacteria
have been identified suggesting that the number is actually
much higher [3]. Moreover, a major gap exists regarding our
understanding of whether microbes and viruses, which are not
generally recognized to cause chronic illnesses, show more
complex interactions in chronic diseases. High-throughput DNA
sequencing has been used as one approach to catalogue the
human microbiome [3]. Several of these comprehensive DNA-
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based metagenomic studies have focused on the bacteria of
the gut and identified microbial imbalances (called dysbiosis) in
several chronic diseases including Crohn’s disease [4,5], type
2 diabetes [6,7] and obesity [8,9]. In the case of type 2 diabetes
patients, an increase in the abundance of several types of
pathogenic bacteria, as well as a decrease in butyrate-
producing bacteria were detected [6]. While these
metagenomics studies have been highly informative, broad,
quantitative, host immune profiles have not been used to study
host-infectious agent interactions. In the current study we
focused on whether humoral profiles against multiple infectious
agents were altered in several chronic diseases.
Antibody detection is an important criterion for diagnosis of
many pathogens and is important for understanding and
monitoring immune responses to infectious agents and
vaccines [10]. In many cases, antibody levels can vary over
time and can be used to monitor pathogen clearance,
dormancy, reinfection and/or reactivation. Despite the
usefulness of clinical immunoassays, most current
technologies do not offer the sensitivity and specificity needed
to broadly assess humoral responses against multiple
infectious agents on the same diagnostic platform. We have
developed Luciferase Immunoprecipitation Systems (LIPS) to
generate high definition antibody profiles for infection and
autoimmune diagnostics and monitoring humoral responses
against a variety of infectious agents [11]. LIPS is based on
chimeric genes encoding target antigens that are fused to
Renilla luciferase and expressed in mammalian cells. Crude
extracts of light emitting antigens are then prepared without
purification and employed in immunoprecipitation assays to
quantify specific antibodies. LIPS offers a wide dynamic range
of antibody detection, which can be used to distinguish different
clinical conditions caused by the same infectious agent [12,13].
Due to its standard format, LIPS is an ideal technology to
generate antibody profiles against multiple infectious agents in
parallel and forms the basis of the current report.
We hypothesized that antibody profiles against multiple
infectious agents might be altered in chronic disease, where
the immune system is compromised, reflecting the interplay
between infection by these agents, host immune responses
and/or disease activity. To test this hypothesis, we examined
three different disease cohorts: patients with IFN-γ AAB [14],
HIV infection and SjS [15]. While immunodeficiency caused by
HIV infection has been extensively studied, less is known about
patients with IFN-γ AAB who are immunocompromised due to
autoantibodies that neutralize IFN-γ cytokine signaling activity
making them particular susceptibility to severe infection by a
variety of non-tuberculosis mycobacteria [14]. Sjögren’s
syndrome (SjS) is a relatively common autoimmune disease
characterized by immune attack on the salivary and lacrimal
glands, which has been proposed to potentially have an
infectious basis. Here from our study of patients and cases
from three chronic diseases, we provide evidence that altered
antibody profiles against common infectious agents are a
frequent phenomenon in chronic immune disease and suggest
that this approach might be useful for studying immune function
and patient subsets in these and other diseases.
Material and Methods
Ethics Statement
The studies were approved by Institutional Review Boards of
National Institute of Allergy and Infectious Disease or National
Institute of Dental and Craniofacial Research. Informed written
consent was obtained from all subjects in accordance with the
human experimentation guidelines of the Department of Health
and Human Services at the NIH, and the studies were
conducted according to the principles expressed in the
Declaration of Helsinki.
Patient cohorts and control subjects
To explore the interplay between infection and chronic
immune disease, we studied three different disease cohorts.
For a group of immunodeficient patients, an HIV cohort was
chosen. The two other cohorts studied were autoimmune
conditions: patients with IFN-γ AAB [14] and SjS [15]. The IFN-
γ AAB cohort comprised patients (n=23) showing high levels of
autoantibodies against IFN-γ (Table S1). All 23 IFN-γ AAB
patients used in our study had the defining feature of this
syndrome, infection by a variety of nontuberculous
mycobacteria and 11 of the patients also had other
opportunistic infections. Geographically matched blood donors
from Taiwan and Thailand without autoantibodies against IFN-γ
were used as controls (control group A; n=22). The
characteristics of both the cases and controls are shown in
Table S1 and were randomly selected from a larger group of
samples that has been previously described [14].
The HIV cohort contained HIV-infected patients (n=23) and
healthy blood donors (n=23; control group B), which were
obtained from the NIH Clinical Center, NIH, Bethesda, MD
under IRB-approved protocols (Table S2). To minimize bias
due to severe immunodeficiency, the HIV patients utilized in
the study were randomly selected from a larger group of
patients with relatively normal CD4 counts (mean = 530
cells/mm3) representing untreated and ART-treated patients.
The healthy control subjects used for comparison were also
randomly selected and had similar age range and gender ratio
(Table S2).
For the SjS cohort, 23 serum samples from SjS patients and
23 blood donors (control group C) were obtained from the NIH
Clinical Center, NIH, Bethesda, MD under IRB-approved
protocols (Table S3). Due to the known heterogeneity of SjS,
the patient samples selected for this study met an additional
criterion of demonstrating autoantibodies against the known
clinically useful SSA autoantigen (Table S3). Eleven of the
blood donors from control group B were also used as controls
in control group C.
Infectious disease targets for LIPS serological analysis
We utilized the LIPS technology for evaluating antibody
response against 13 different infectious agents including a
variety of viral and fungal targets. The rationale for examining
antibody responses against six different human herpesviruses
(HSV-1, HSV-2, VZV, EBV, CMV and HHV-6) was because of
their relative high seroprevalence in different human
Antibody Infection Profiles in Chronic Disease
PLOS ONE | www.plosone.org 2 December 2013 | Volume 8 | Issue 12 | e81635
populations and their potential role in causing human disease,
autoimmunity and their propensity for showing reactivation in
immunodeficiency [16]. Similarly, the coxsackievirus B4 virus,
as well as three additional enteroviruses (AstV-A1, poliovirus
and Cosavirus), were examined due to their potential role in
autoimmunity [17]. Antibody responses against influenza were
examined as a potential general marker of humoral immunity.
Finally, two fungal targets, Pneumocystis jirovecii and Candida
albicans, were included in the panel because these agents
cause significant infections in immunocompromised patients
[18].
Many of the LIPS antigens used for the infectious agents
described above have been previously reported along with their
diagnostic performance including the gG-1 of herpes simplex
virus-1 (HSV-1) [19], gG-2 of herpes simplex virus-2 (HSV-2)
[19], BFRF3 (p18), BZLF2, BHRF1, and BMRF1 of Epstein-
Barr virus (EBV) [20], pp165 and pp65 of Cytomegalovirus
(CMV) [21], p101 of Human herpes virus-6B (HHV-6) [22] ,
HA2 of influenza [20], capsid of HMO-astrovirus [23] and the
MSG-14 of Pneumocystis jirovecii [24]. New antigen constructs
for additional infectious agent targets were chosen based on
their known antigenicity and were generated essentially as
described using the pREN2 and pREN3S vector [24]. These
new constructs included the VP1 capsid protein of poliovirus
(GenBank accession KC848180), the VP1 capsid protein of
coxsackievirus B4 virus (GenBank accession KC848181), and
enolase from C. albicans (GenBank accession KC848182).
Antigen fusions of the glycoprotein E (gE) antigen from
varicella-zoster virus (VZV) and a helicase target (GenBank
accession KC848185) from a newly described picornavirus,
HCoSV-A [25], were also used and will be described in detail in
forthcoming manuscripts. DNA sequencing confirmed the
integrity of all newly described plasmids.
LIPS antibody testing
A 96-well microtiter plate format of LIPS was employed to
evaluate antibodies in the serum samples for each of the 13
antigen targets. For these studies, three master plates of the
serum samples were constructed for each cohort for reiterative
antibody testing. For generating the master plates, serum
samples were diluted 1:10 in assay buffer A (20 mM Tris, pH
7.5, 150 mM NaCl, 5 mM MgCl2, 1% Triton X-100) in a 96-deep
well microtiter plate and then stored at 4° C until use. Additional
buffer blanks were also included to monitor background binding
activity of the assays. As described in a detailed publication
and corresponding video, LIPS testing is initiated by adding
40 μl of buffer A, 10 μl aliquots of serum (equivalent to 1 μl of
serum) from the master plate, and 50 μl of each Ruc-antigen
Cos1 cell extract typically containing an equivalent of 107 light
units (LU) were added to a polypropylene plate [26]. After
one hour incubation at room temperature with shaking, the
mixture containing IgG antibody-antigen complexes are
transferred to a microtiter filter plate containing protein A/G
beads for one hour additional incubation. Next the filter plate is
washed with buffer on a vacuum manifold to remove unbound
Renilla luciferase–tagged antigens. LU are then measured
using a luminometer following the addition of coelenterazine
substrate. All LU data were obtained from the average of at
least two separate experiments and were not corrected for
background protein A/G bead binding.
Data and statistical analysis
The antibody levels in the three cohorts were analyzed using
GraphPad Prism software (San Diego, CA) and JMP (Cary,
NC). Geometric mean antibody levels (GML), expressed as
mean log (10) LU and 95% CI, were calculated and presented
as antilog values. Unless otherwise stated, the non-parametric
Mann-Whitney U statistical test was used for comparison of
antibody titers in the control and patient groups. Since this
study was exploratory, P values were not corrected for multiple
comparisons and were rounded off to the most significant digit.
For the three cohorts, the antibody responses against the 13
different infectious agents are shown from left to right
corresponding to yeast, fungus, enteroviruses, influenza and
herpesviruses. Correlation calculations of the antibody levels
against the different infectious agents in each study were
determined using the Pearson correlation analysis. The
prevalence of infection of these viruses in the different cohorts
was also calculated since the diagnostic performance of LIPS
for several herpes viruses have been validated in previous
studies [19-22] (Table S4).
Data mining
To potentially identify combinations of antibody targets useful
in distinguishing patients from controls in the three studies, the
RapidMiner open-source suite of data mining and machine
learning software (www.rapidminer.com) was employed [27].
Principal component analysis (PCA) was used to analyze the
antibody response data [28]. For the analysis, antibody
responses were normalized and evaluated as a combined test
to derive the corresponding principal components (PC)
showing the greatest variation between all samples in each
cohort. For each cohort study, PC1 and PC2 showed the
highest values for describing the data. The GraphPad software
was then used to graph on a biplot the PC1 vs. PC2 values for
each cohort comprising all the patient and control subjects. For
the IFN-γ AAB and HIV cohorts, a manually derived separation
line was used to optimally separate the control subjects from
patients.
Results
Humoral profiles in patients with high levels of
neutralizing autoantibodies against interferon-γ
Recently we described a novel immunodeficiency syndrome
in a cohort of patients from Taiwan and Thailand showing
unusual opportunistic infections caused by high levels of
pathogenic autoantibodies against interferon-γ (IFN-γ AAB)
[14]. The clinical characteristics of the IFN-γ AAB patients
(n=23) along with the corresponding control subjects (control
group A; n=22) are shown in Table S1. While the defining
clinical feature of IFN-γ AAB patients is the presence of non-
tuberculosis mycobacterial infection, the full spectrum of
susceptibility to other infections for these patients is not known.
To potentially characterize the interplay between additional
Antibody Infection Profiles in Chronic Disease
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infectious agents in these patients compared to controls, we
employed LIPS to profile antibodies against 13 different
infectious agents including viral and fungal agents. As shown in
Figure 1, the geometric mean antibody levels plus 95%
confidence interval for the patient and control groups against
the 13 different infectious agents often showed a large dynamic
range of detection often spanning 100-fold (note: Y axis is log10
scale). The antibody levels for many of the agents, including
influenza, HCoSV-A and coxsackievirus, showed no statistical
difference between the IFN-γ AAB patients and control group.
However, five antigens demonstrated statistical differences
between IFN-γ AAB patients and disease controls (Figure 1).
Antibodies against VZV demonstrated the greatest difference
with a geometric mean level (GML) in IFN-γ AAB patients of
217,800 LU [95% confidence interval (CI); 173,400-273,500],
which was significantly higher (Mann-Whitney U test;
p=0.0003) than the controls with a value of 85,720 LU (95% CI;
50,140-146,500). Antibody levels against three other targets,
EBV, CMV, and Candida albicans, also showed significantly
higher values in the IFN-γ AAB patients compared to the
controls with p values of 0.002, 0.003, and 0.03, respectively
by Mann-Whitney U testing (Figure 1). As shown in Table S4,
the seroprevalence of HSV-1 infection was more common (p=
0.04) in the IFN-γ AAB patients compared to the controls, but
the other seroprevalence of the four other herpesviruses
(HSV-2, EBV, CMV and HHV-6) were similar between the two
groups.
The IFN-γ AAB group displayed lower antibody levels in
comparison to the control group only against polio vaccine
(Figure 1). The GML of antibodies against the VP1 protein of
the polio vaccine in the IFN-γ AAB subjects was 27,210 LU
(95% CI; 17,350-42,690) and was lower (p=0.04) than the
controls with a value of 47,640 LU (95% CI; 24,180-93,870).
Overall, these profiles demonstrate significant differences in
immune response to common infectious agents in IFN-γ AAB
patients in comparison to matched controls.
Independent validation of altered anti-CMV and anti-
EBV antibody profiles in patients with anti-IFN-γ
autoantibodies
Based on the higher antibody levels against four different
herpes viruses antigenic targets in the IFN-γ AAB subjects
compared to the controls, one other CMV and three additional
EBV antigenic targets were evaluated in order to independently
validate whether there were increased antibody levels against
these two herpes viruses in the IFN-γ AAB group. Similar to the
results with the BFRF3 capsid protein of EBV, all three of these
lytic EBV targets, BMRF1, BZLF2, and BHRF1, showed higher
levels of antibodies in the IFN-γ AAB patients compared to the
controls with p values of 0.0002, <0.0001 and 0.01,
respectively (Figure 2). The additional CMV target, pp65, also
demonstrated higher levels of antibodies in the IFN-γ AAB
group compared to controls, which were statistically significant
(p=0.002) (Figure 2). Together these results highlight the fact
that the IFN-γ AAB patients have abnormally high levels of
antibodies against several herpes viruses including EBV and
CMV.
Altered antibody profiles against common infectious
agent in HIV patients
In light of the finding that there was an altered antibody
profile in the IFN-γ AAB patients, the antibody profile
differences against these same infectious agents was next
examined in patients with immunodeficiency caused by HIV.
The clinical characteristics of the HIV patients (n=23) along
with the corresponding blood donor controls (control group B;
n=23) are shown in Table S2. Comparison of the controls with
HIV subjects demonstrated that antibodies against many of the
infectious agents including VZV, influenza, and HCoSV-A virus,
were similar between the two groups and were not statistically
different (Figure 3). In contrast, antibody responses against
four infectious agents, CMV, HSV-2, EBV, and C. albicans,
showed significantly higher levels in the HIV subjects
compared to the healthy blood donors (Figure 3). As shown in
Figure 3, the GML of anti-CMV antibody was approximately 16-
fold higher in HIV patients compared to the controls (Mann-
Whitney U test; p=0.0008). However, it should be noted that
there was a marked increased prevalence of anti-CMV
antibodies in HIV patients (87%; 20/23) compared to healthy
blood donors (43%; 10/23), thereby skewing the results (Table
S4). Similarly, the anti-HSV-2 specific antibodies were
statistically higher in the HIV-infected subjects (p=0.0008), and
analysis of HSV-2 seropositivity revealed that the HIV subjects
showed 78% seropositivity vs. the blood donors with 17%
seropositivity (Table S4). The seroprevalence of anti-EBV
antibodies in the HIV and control subjects were similar, but the
GML of anti-EBV antibodies in the HIV group was
approximately 18 times higher than that of the GML of the
blood donor group (p=0.002). Lastly, the antibody levels
against the C. albicans antigen in the HIV patients was six
times higher than the control blood donor group (p=0.01)
(Figure 3). In comparison to the control group, HIV patients had
significantly lower titers, against polio, coxsackievirus B4 and
HHV6-B compared to controls with p values of 0.0005, 0.0008
and 0.002, respectively (Figure 3). Analysis of the overall
antibody data from the HIV patients against all 13 targets
revealed that poorly correlated with each other. However,
antibodies against two of the targets, poliovirus VP1 capsid and
coxsackievirus B4 VP1 capsid protein weakly correlated
(R=0.54; p>0.007). Protein alignment of the poliovirus and
coxsackievirus B4 VP1 capsid proteins revealed 50% similarity
(data not shown).
Antibody profiles against common infectious agents in
Sjögren’s syndrome patients
Sjögren’s syndrome (SjS) is a relatively common
autoimmune disease characterized by immune attack on the
salivary and lacrimal glands [15]. It is not known if infectious
agents play a role in the pathogenesis and symptomatology of
SjS. To potentially characterize the interplay of infectious
agents in the SjS cohort, we profiled antibodies against the
panel of infectious agents (Table S3). As shown in Figure 4,
comparison of blood donor controls (n=23) with SjS patients
(n=23) showed that the antibody level against VZV, CMV,
HSV-1, influenza and several other agents were not statistically
different between the two subject groups. However, antibody
Antibody Infection Profiles in Chronic Disease
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levels against the EBV capsid protein showed slightly higher
levels in the SjS patients compared to controls. The GML
against EBV in the SjS patients was 888,000 LU (95% CI;
441,644-1,785,000) and was higher (p=0.03) than the controls
with a value of 650,269 LU (95% CI; 340,582-1,242,000).
Besides the higher levels of antibodies against EBV in the
SjS group, antibodies against three infectious agents, HCoSV-
A, poliovirus, and coxsackievirus, displayed lower levels in the
SjS group compared to controls (Figure 4). The GML of
antibodies against the HCoSV-A in the SjS patients showed a
value of 46,280 LU (95% CI; 26,005-82,380) and was 5-fold
lower (p=0.004) than the blood donor controls with a value of
200,784 LU (95% CI; 124,800-323,100). Antibody responses
against the coxsackievirus B4 and polio also had higher GML
Figure 1.  Antibody profiles against common infectious agents in IFN-γ AAB patients vs. controls.  The geometric mean level
and 95% CI for antibody levels against each of the 13 infectious disease targets were plotted for the 23 controls (black) and 23 IFN-
γ AAB patients (red) on the Y-axis using a log10 scale. The different infectious agents were manually organized as described in the
material and methods. Statistically significant p values between the two groups are shown and were calculated using the Mann-
Whitney U test, whereby higher antibody levels in IFN-γ AAB patients are colored red, while higher levels in the controls are colored
black.
doi: 10.1371/journal.pone.0081635.g001
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in the controls compared to the HIV patients and were
statistically significant with P values of 0.04 and 0.02,
respectively (Figure 4).
Principal component analyses reveals patient and
control clusters
One goal of these studies was to determine if the antibody
landscape against common infectious agents in three diseases,
in which the immune system is compromised, was different in
patients vs. controls. Since our goal was to look broadly at
antibody profiles, principal component analysis (PCA) was
used to determine if any linear combinations of antibodies
might be useful in differentiating patients from controls. The
various PC values were derived for each cohort. From these
analyses, the first two principal components, PC1 and PC2, in
each case of the cohorts explained the largest variance of the
Figure 2.  Validation of increased anti-EBV and anti-CMV antibodies in IFN-γ AAB patients.  The antibody responses for (A)
EBV BMRF (B) EBV BZLF2 (C) EBV BHRF and (D) CMV pp65 in the 23 controls (black) and 23 IFN-γ AAB patients (red) are
plotted on the Y-axis using a log10 scale. Each symbol represents one individual. The geometric mean level and 95% CI for antibody
levels are also shown. P values comparing the two groups were calculated using the Mann-Whitney U test.
doi: 10.1371/journal.pone.0081635.g002
Antibody Infection Profiles in Chronic Disease
PLOS ONE | www.plosone.org 6 December 2013 | Volume 8 | Issue 12 | e81635
antibody data. In the case of the IFN-γ AAB patients and
controls, PC1 and PC2 explained 0.18 and 0.16, respectively of
the variance from the 13 antibodies that were profiled. A biplot
of PC1 vs. PC2 showed that many of IFN-γ AAB patients
clustered from the controls, in which a manually derived
separation line had a diagnostic performance of 86% sensitivity
and 79% specificity in distinguishing cases from controls
(Figure 5A). For the HIV cohort, PC1 and PC2 explained
approximately 30% of the variance and a corresponding
separation line demonstrated a modest ability to differentiate
HIV patients from controls with 92% sensitivity and 79%
specificity (Figure 5B). However, for the SjS cohort a similar
plot of PC1 vs. PC2 was unable to clearly separate the patients
from controls (Figure 5C). Additional PCA analysis of the SjS
cases and controls using the four most informative infectious
agent antibody responses also had poor performance for
Figure 3.  Humoral responses against common infectious agents in HIV patients vs. controls.  The geometric mean level and
95% CI for antibody levels against each of the 13 infectious disease targets were plotted for the 23 controls (black) and 23 HIV
patients (blue) on the Y-axis using a log10 scale. Statistically significant p values between the two groups are shown and were
calculated using the Mann-Whitney U test, whereby higher antibody levels in HIV patients are colored blue, while higher levels in the
controls are colored black.
doi: 10.1371/journal.pone.0081635.g003
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distinguishing the two groups (data not shown). Nevertheless,
the finding that the IFN-γ AAB and HIV immunodeficiency
cohorts had different PCA profiles between the cases and
controls highlights the complex matrix of interactions that occur
between these infectious agents in these two diseases.
Discussion
Increasing evidence suggest that the complicated repertoire
and even exposure against many infectious agents, which do
not cause overt disease, may influence human health and the
immune system [17]. In an attempt to understand the impact of
a selected group of common infectious agents, the purpose of
this study was to determine whether there were altered
patterns of humoral responses against a panel of 13 agents in
Figure 4.  Antibody profiles against common infectious agents in SjS patients vs.  controls.
The geometric mean level and 95% CI for antibody levels against each of the 13 infectious disease targets were plotted for the 23
controls (black) and 23 SjS patients (green) on the Y-axis using a log10 scale. Statistically significant p values between the two
groups are shown, whereby higher antibody levels in SjS patients are colored green, while higher levels in the controls are colored
black.
doi: 10.1371/journal.pone.0081635.g004
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three chronic diseases. The LIPS technology was used to
systematically generate broad antibody profiles against these
multiple agents. All three of the diseases studied showed
significant alterations in antibody responses against single
infectious agents. The multivariate PCA analysis using the
cumulative antibody data for the IFN-γ AAB and HIV cohorts
also showed modest ability to separate the cases from controls
supporting the idea that complex interactions occur between
these infectious agents in these two diseases.
In the patients with the autoimmune immunodeficiency
syndrome caused by IFN-γ AAB, higher levels of antibody were
observed against several different herpes viruses and C.
albicans compared to controls. The finding that the most
informative antibody response distinguishing IFN-γ AAB
patients from controls was against the human herpesvirus,
VZV, is consistent with the known clinical presentation of
disseminated VZV infection in these patients [14]. A recent
report has also documented that IFN-γ AAB patients often
exhibit VZV reactivation [29]. In addition to VZV, the IFN-γ AAB
patient group also showed significantly elevated antibody levels
against other herpes virus members including CMV and EBV.
The results showing elevated antibodies against multiple
herpes viruses likely reflects the immunosuppression caused
by the loss of IFN-γ and supports an important role of IFN-γ in
controlling a number of different herpes virus infections. The
broad antibody profiling strategy described here may also be a
useful screening approach for identifying the repertoire of
infectious agents that are affected by IFN-γ activity.
From antibody profiling the HIV patients both increased and
decreased antibody responses were detected against several
infectious agents relative to the healthy controls. Four
infectious agents, CMV, HSV-2, EBV, and C. albicans, elicited
significantly higher levels of antibody levels in HIV patients
compared to controls. The increased levels of antibodies
against EBV and CMV in HIV patients are consistent with
previous studies [30-33] and are likely due to the increased
viral loads of these herpesviruses that are present in HIV
patients [30,34]. In addition to the increased antibody
responses seen in HIV patients, the HIV patients compared to
controls demonstrated significantly blunted antibody responses
against poliovirus, coxsackievirus and HHV-6B. While the exact
reason is not known, it may reflect differences in exposure,
abnormal B-cell activity and/or related immune dysfunction
resulting in the loss of particular immune cell subsets. Both
polio and coxsackievirus are enteric pathogens, and recent
metagenomic studies have shown that there is an expansion of
the enteric virome and other alterations in HIV patients [35], as
well as Simian Immunodeficiency Virus-infected macaques
[36]. It is also important to point out that the two
immunodeficiency syndromes studied, IFN-γ AAB and HIV-
infected patients, showed several differences in antibody
responses. First, unlike the higher VZV antibody levels seen in
IFN-γ AAB patients, no elevation of VZV antibodies was
detected in HIV patients. Moreover, the decreased antibody
levels in HIV patients seen against coxsackievirus B4 and
HHV-6B were not observed in the IFN-γ AAB group. These
subtle humoral response differences are plausible because the
patients with IFN-γ AAB are only missing a single cytokine,
while the HIV patients have a loss of CD4+ T-cell activity.
Despite these noticeable differences, additional studies are
needed to determine whether the results are disease-specific
or reflect the distinct geographically-matched controls used for
comparison in each of the cohorts.
In contrast to the INF-γ AAB and HIV patients, SjS patients
showed elevated antibody levels against only EBV compared
to controls. While several studies have implicated EBV in the
pathogenesis of SjS [37-39], the antibody levels against the
EBV capsid protein observed in our study were only modestly
increased in the SjS group compared to controls. It is also
important to point out that increased EBV antibody levels were
Figure 5.  Principal component analysis of the antibody landscape reveals disease-specific clusters for the IFN-γ AAB and
HIV cohorts.  For each of the three studies, PCA was used separately to calculate the PC1 and PC2 values from the antibody
levels for the 13 infectious agents. The PC1 vs. PC2 values for all the subjects from the (A) IFN-γ AAB (B) HIV and (C) SjS cohorts
were then graphed on a biplot. In each panel, the control subjects are colored black and the IFN-γ AAB, HIV and SjS patients are
colored red, blue and green, respectively. For the IFN-γ AAB and HIV cohorts, the dotted line represents a manually assigned
distinction point for optimally discriminating the control subjects from patients.
doi: 10.1371/journal.pone.0081635.g005
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also seen in both the IFN-γ AAB and HIV patients, suggesting
the possibility that the increased EBV antibodies in SjS patients
represents viral reactivation due to immunosuppression that is
associated with disease pathogenesis or even treatment. The
lack of significant antibody differences in SjS patients against
many of the targets including CMV, C. albicans and HHV-6
also suggests that these agents are likely not to be directly
involved in the pathogenesis of this disease. The findings of
lower antibody levels against three enterovirus targets
including poliovirus, coxsackievirus and HCoSV-A compared to
controls was unexpected because SjS patients generally
secrete high amounts of total immunoglobulin. The lower
antibody levels against HCoSV-A, a new human enterovirus
[25], were also not observed in the HIV or IFN-γ AAB patients.
The lower antibody levels against these three enterovirus
targets may reflect B-cell dysfunction, immunosuppression
related to treatment, failure to produce long-lived plasma cells
or altered pathogen exposure. Interestingly, a recent study has
demonstrated that the gut microbiome can regulate
autoimmunity via its effects on sex hormones [40]. Due to the
much higher prevalence of SjS in females compared to males
[15], examining antibody responses against diverse bacteria in
SjS patients is an additional rich area of exploration.
In conclusion, our results suggest that this general approach
of antibody profiling many different agents could be used to
more broadly identify viruses, bacteria and other organisms
that might contribute to inflammation and chronic immune
activation, and/or yield further insight into disease subsets and
possible comorbid conditions. It is also likely that the
performance of this approach could be improved by additional
informative antibody targets. Since LIPS requires small
amounts of serum, over 500 different agents could be profiled
with approximately 1 ml of serum. This antibody profiling
approach might also be useful both for exploring the
pathogenesis and diagnosis of diseases that lack readily
definable clinical tests such as chronic fatigue syndrome and
Kawasaki disease. Future studies incorporating an even
broader array of targets including against different bacteria and
viruses are likely to uncover more evidence of dysbiosis in
these and other diseases.
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